Celgene Battles $40B FCA Suit Over Off-Label Promos
Celgene Corp. on Monday pressed a California federal judge to end a whistleblower's $40 billion False Claims Act suit over off-label promotion of cancer drugs Thalomid and Revlimid, asserting that government...To view the full article, register now.
Already a subscriber? Click here to view full article